Bone histomorphometry after treatment with teriparatide (PTH 1-34) in a patient with adynamic bone disease subsequent to parathyroidectomy

NDT Plus

Volumn 2, Issue 1, 2009, Pages 49-51

  Lehmann, Gabriele ^a   Ott, Undine ^a   Maiwald, Jörg ^b   Wolf, Gunter ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b Dialysis Center and Nephrological Surgery   (Germany)

Author keywords

Adynamic bone disease; End stage renal disease; Histomorphometry; Teriparatide therapy

Indexed keywords

CALCITRIOL; CALCIUM ACETATE; COLECALCIFEROL; PARATHYROID HORMONE[1-34]; SEVELAMER;

ADULT; ANAMNESIS; ARTICLE; AUTOTRANSPLANTATION; BONE BIOPSY; BONE DISEASE; BONE MINERALIZATION; BONE REMODELING; CASE REPORT; CLINICAL FEATURE; DISEASE SEVERITY; DRUG EFFECT; HEMODIALYSIS; HUMAN; HUMAN CELL; HYPERTHYROIDISM; MALE; MORPHOMETRICS; PARATHYROIDECTOMY; PRIORITY JOURNAL;

EID: 58449109471     PISSN: 17530784     EISSN: 17530792     Source Type: Journal    
DOI: 10.1093/ndtplus/sfn169     Document Type: Article

References (10)

1. Atsumi K, Kushida K, Yamazaki K et al. Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis 1999; 33: 287-293
2. London GM, Matry C, Marchais SJ et al. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 2004; 15: 1943-1951
3. Lehmann G, Stein G, Hüller M et al. Specific measurement of PTH (1-84) in various forms of renal osteodystrophy (ROD) assessed by bone histomorphometry. Kidney Int 2005; 68: 1206-1214
4. Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyrioid hormone (PTH) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-1441
5. Dempster DW, Cosman F, Kurland ES et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and bone turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001; 16: 1846-1853
6. Orwoll ES, Scheele WH, Paul S et al. The effect of teriparatide [(human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003; 18: 9-17
7. Saluski IB, Goodman WG. Adynamic renal osteodystrophy: is there a problem? J Am Soc Nephrol 2001; 12: 1978-1985
8. Shiohara M, Shiozawa R, Kurata K et al. Effect of parathyroid hormone administration in a patient with severe hypoparathyroidism caused by gain-of-function mutation of calcium-sensing receptor. Endocrinol Jpn 2006; 53: 797-802
9. Miller PD, Schwartz EN, Chen P et al. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int 2007; 18: 59-68
10. Hodsman AB, Bauer DC, Dempster DW et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocrin Rev 2005; 26: 688-703